{"filing":{"accession_number":"0001193125-26-345672","cik":"0001528115","ticker":"ANNX","company_name":"Annexon, Inc.","form":"8-K","filing_date":"2026-08-12","report_date":"2026-08-12","primary_document":"d119960d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1528115/000119312526345672/d119960d8k.htm"},"events":[{"id":26994,"run_id":24561,"accession_number":"0001193125-26-345672","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Annexon reported second quarter 2026 financial results, including R\u0026D expenses of $46.6M, G\u0026A expenses of $10.6M, and a net loss of $55.3M ($0.28 per share), with a cash position of $209.2M and anticipated runway into 2028.","company_name":"Annexon, Inc.","ticker":"ANNX","filing_date":"2026-08-12","form":"8-K","submitted_at":null,"items":[{"id":28317,"accession_number":"0001193125-26-345672","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release disclosing Annexon's second quarter 2026 financial results, including R\u0026D expenses ($46.6M), G\u0026A expenses ($10.6M), and net loss ($55.3M or $0.28 per share), along with cash position ($209.2M) and anticipated runway into 2028. The press release is titled \"Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones\" and is furnished as Exhibit 99.1 pursuant to Item 2.02, the standard Item for earnings disclosures.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T10:31:47.957613+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":26995,"run_id":24561,"accession_number":"0001193125-26-345672","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Annexon announced a strategic expansion of its Phase 3 ARCHER II trial for vonaprument by adding a Month 24 dual primary endpoint alongside the existing Month 15 endpoint, and launched an open-label extension study.","company_name":"Annexon, Inc.","ticker":"ANNX","filing_date":"2026-08-12","form":"8-K","submitted_at":null,"items":[{"id":28318,"accession_number":"0001193125-26-345672","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces a strategic expansion of Annexon's Phase 3 ARCHER II trial for vonaprument by adding a Month 24 dual primary endpoint alongside the existing Month 15 endpoint, and the launch of an open-label extension study. This is a material operational/clinical development affecting the company's drug development strategy and timeline, but does not fit neatly into specific categories like earnings_release, exec_appointment, or ma_activity. The event is clearly operational in nature—a significant clinical trial design modification and new study launch—making operational_other the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T10:31:47.957613+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":28317,"accession_number":"0001193125-26-345672","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release disclosing Annexon's second quarter 2026 financial results, including R\u0026D expenses ($46.6M), G\u0026A expenses ($10.6M), and net loss ($55.3M or $0.28 per share), along with cash position ($209.2M) and anticipated runway into 2028. The press release is titled \"Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones\" and is furnished as Exhibit 99.1 pursuant to Item 2.02, the standard Item for earnings disclosures.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T10:31:47.957613+00:00","company_name":"Annexon, Inc.","ticker":"ANNX","filing_date":"2026-08-12"},{"id":28318,"accession_number":"0001193125-26-345672","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces a strategic expansion of Annexon's Phase 3 ARCHER II trial for vonaprument by adding a Month 24 dual primary endpoint alongside the existing Month 15 endpoint, and the launch of an open-label extension study. This is a material operational/clinical development affecting the company's drug development strategy and timeline, but does not fit neatly into specific categories like earnings_release, exec_appointment, or ma_activity. The event is clearly operational in nature—a significant clinical trial design modification and new study launch—making operational_other the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T10:31:47.957613+00:00","company_name":"Annexon, Inc.","ticker":"ANNX","filing_date":"2026-08-12"}]}